Novus Therapeutics (NASDAQ:NVUS) shares are trading higher on Tuesday after the company announced the purchase of Anelixis Therapeutics.
Novus Therapeutics shares were trading up 179.68% at $1.06 on Tuesday during the time of publication. The stock has a 52-week high of $1.45 and a 52-week low of 25 cents.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
Novus Therapeutics is engaged in the biotechnology sector. As a pharmaceutical company it is focused on the acquisition, development, and commercialization of ear, nose, and throat related products. It has two platforms: Foam Platform(OP0201 and OP0202) and Surfactant Program(OP0201). OP0102 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP0201 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction.
